Volume: 43 Issue: 2
Year: 2023, Page: 625-629, Doi: https://doi.org/10.51248/.v43i02.2774
Introduction and Aim: Though there are many drugs approved for treatment of Alzheimer’s disease (AD), there is scope for exploring newer molecules for AD management, especially considering the side effects and drug interaction profile of the existing drugs. The present study was conducted to assess the neuroprotective properties of valeric acid by estimating the five neurotransmitters in the hippocampus of Wistar albino rats in an aluminium induced AD model.
Materials and Methods: In this experimental study design effects of valeric acid, piracetam and rivastigmine were evaluated for changes in neurotransmitter levels. Seven groups were made out of 42 Wistar albino rats (male). Aluminum chloride (AlCl3) (100 mg/kg body weight) was given orally for 42 days to cause AD. As a treatment, valeric acid (50 mg/kg body weight) was administered to rats in group 3, piracetam was given to group 4, rivastigmine to group 5, and a combination of piracetam and valeric acid to group 6 and valeric acid and rivastigmine to group 7 rats. After this, rat hippocampus is used to estimate acetylcholine (ACH), GABA, glutamate, dopamine, and serotonin levels.
Results: ACH levels of the hippocampus in all treated groups (groups 3 to 7) showed more increase in comparison to positive control (group 2) group. And remaining all groups demonstrated a considerable rise in GABA, glutamate, dopamine, and serotonin levels, demonstrating the reversed AlCl3-induced impairment.
Conclusion: The neurotransmitter levels in aluminum chloride-induced neurological impairment appear to be significantly improved by valeric acid and its use in combination with piracetam and rivastigmine.
Keywords: Alzheimer’s disease; acetylcholine; GABA; glutamate; dopamine; serotonin; valeric acid.
1. Amanzadeh, J. E., Esmaeili, A., Rahgozar, S., Noorbakhshnia, M. Quercetin-conjugated superparamagnetic iron oxide nanoparticles protect AlCl3-induced neurotoxicity in a rat model of Alzheimer’s disease via antioxidant genes
APP gene, and miRNA-101. Front Neurosci. 2021 Feb; 14: 598617.
2. Singh, N.A., Bhardwaj, V., Ravi, C., Ramesh, N., Mandal, A.K.A., Khan, Z.A. EGCG nanoparticles attenuate aluminum chloride induced neurobehavioral deficits, beta amyloid and tau pathology in a rat model of Alzheimer’s disease. Front Aging Neurosci. 2018 Aug; 10:244.
3. Mahdi, O., Chiroma, S.M., Hidayat, B.M.T., Mohd, N.N.H., Mat, C.N., Jagadeesan, S., et al., WIN55, 212-2 attenuates cognitive impairments in AlCl3+ d-Galactose-Induced Alzheimer’s disease rats by enhancing neurogenesis and reversing oxidative stress. Biomedi. 2021 Sep; 9(9):1270.
4. Rather, M.A., Thenmozhi, A.J., Manivasagam, T., Bharathi, M.D., Essa, M.M., Guillemin, G.J. Neuroprotective role of Asiatic acid in aluminium chloride induced rat model of Alzheimer’s disease. Front Biosci (Schol Ed). 2018 Jan; 10(2):262-275.
5. Ray, B., Maloney, B., Sambamurti, K., Karnati, H.K., Nelson, P.T., Greig, N.H., et al., Rivastigmine modifies the α-secretase pathway and potentially early Alzheimer’s disease. Translational Psychiatry. 2020 Feb;10(1):47.
6. Nafea, M., Elharoun, M., Abd-Alhaseeb, M.M., Helmy, M.W. Leflunomide abrogates neuroinflammatory changes in a rat model of Alzheimer’s disease: the role of TNF-alpha/NF-kB/IL-1beta axis inhibition. Naunyn-Schmiedeb. Arch. Pharmacol. 2023 Mar;396(3):485-498.
7. Gregory, J., Vengalasetti, Y.V., Bredesen, D.E., Rao, R.V. Neuroprotective herbs for the management of Alzheimer’s disease. Biomolecules. 2021 Apr;11(4):543.
8. Dadaya, E., Koubala, B., Ndjonka, D., Zingue, S., Laya, A., Atsang, G. Hydromethanolic root extract of Gnidia kraussiana demonstrates anti-inflammatory effect through anti-oxidant activity enhancement in a rodent model of gout. Dose-Response. 2023 Jan;21(1):15593258221148015.
9. John, O.O., Amarachi, I.S., Chinazom, A.P., Adaeze, E., Kale, M.B., Umare, M.D., et al., Phytotherapy: A promising approach for the treatment of Alzheimer's disease. Pharmacol. Res. Commun. 2022 Mar; 2: 100030.
10. Batista, F.C., da Silva, M.P., Zotarelli, F.I.J., Duarte, M.G. Herbal medicine, and climacteric: a systematic review of the main clinical outcomes. Int. J. Nutr. 2023 Mar;16(2).
11. Rodríguez-Cruz, A., Romo-Mancillas, A., Mendiola-Precoma, J., Escobar-Cabrera, J.E., Garcia-Alcocer, G., Berumen, L.C. Effect of valerenic acid on neuroinflammation in a MPTP-induced mouse model of Parkinson’s disease. IBRO Rep. 2020 Jun; 8: 28-35.
12. Gammoh, O., Aburubaiha, Z., Mayyas, A., Alkatib, W., Masarweh, R., Elhajji, F., et al., Valerian and Hops combination versus Escitalopram in models of depression and anxiety: A crosstalk with oxidative stress. Jordan J. Pharm. Sci. 2023 Mar;16(1):124-136.
13. Dulla, B.S., Bindhu, S. A Study on the Effect of Valeric Acid in Alzheimer's Induced Rats by the Estimation of Aβ 1-42 Biomarker. J. Health Allied Sci. NU. 2022 May;12(02):134-138.
14. Al-Attraqchi, O.H.A., Deb, P.K., Al-Attraqchi, N.H.A. Review of the phytochemistry and pharmacological properties of Valeriana officinalis. Curr. Tradit. Med. 2020 Dec;6(4):260-277.
15. Setyawan, A.B., Satria, A.P., Arung, E.T., Paramita, S. Anti-diabetic activity of bee pollen dry extract standardized in alloxan-induced diabetic rats. Sys Rev Pharm. 2023 Feb;14(2);91-93.
16. Pena-Bautista, C., Torres-Cuevas, I., Baquero, M., Ferrer, I., Garcia, L., Vento, M., et al., Early neurotransmission impairment in non-invasive Alzheimer disease detection. Sci Rep. 2020 Oct;10(1):16396.
17. Don-Doncow, N., Vanherle, L., Matthes, F., Petersen, S.K., Matuskova, H., Rattik, S., et al., Simvastatin therapy attenuates memory deficits that associate with brain monocyte infiltration in chronic hypercholesterolemia. NPJ Aging Mech. Dis.2021 Aug; 7(1):1-19.
18. Birks, J.S., Grimley, E.J. Rivastigmine for Alzheimer’s
disease. CDSR. 2015 Apr; 4:CD001191.
19. Czapski, G.A., Strosznajder, J.B. Glutamate and GABA in microglia-neuron crosstalk in Alzheimer’s disease. Int. J. Mol. Sci. 2021 Oct;22(21):11677.
20. Sun, Y., Zhang, H., Zhang, X., Wang, W., Chen, Y., Cai, Z., et al., Promotion of astrocyte-neuron glutamate-glutamine shuttle by SCFA contributes to the alleviation of Alzheimer's disease. Redox Biology. 2023 Mar;102690.
21. Oskouie, A.A., Yekta, R.F., Tavirani, M.R., Kashani, M.S., Goshadrou, F. Lavandula angustifolia effects on rat models of Alzheimer’s disease through the investigation of serum metabolic features using NMR metabolomics. Avicenna J. Med. Biotechnol.2018 Apr;10(2):83.
22. Ceyzeriat, K., Gloria, Y., Tsartsalis, S., Fossey, C., Cailly, T., Fabis, F., et al., Alterations in dopamine system and in its connectivity with serotonin in a rat model of Alzheimer’s disease. Brain Commun.2021 Mar;3(2): fcab029.
23. Marcinkowska, M., Mordyl, B., Fajkis-Zajaczkowska, N., Siwek, A., Karcz, T., Gawalska, A., et al., Hybrid molecules combining GABA-A and serotonin 5-HT6 receptors activity designed to tackle neuroinflammation associated with depression. Eur. J. Med. Chem. 2023 Feb;247:115071.
24. Udo, N., Hashimoto, N., Toyonaga, T., Isoyama, T., Oyanagi, Y., Narita, H., et al., Apathy in Alzheimer’s disease correlates with the dopamine transporter level in the caudate nuclei. Dement. Geriatr. Cogn. Disord. Extra. 2020 Sep;10(2):86-93.
Blessina, Bindhu S., Pramod K. L., Ashaiba Asiamma. Effect of valeric acid on the neurotransmitter levels of hippocampus on Alzheimer’s induced rats. Biomedicine: 2023; 43(2): 625-629